GeneDx Holdings Corp. (WGS) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $53.42: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 32%; Below-average business quality; Negative price momentum.
GeneDx provides exome and whole genome sequencing primarily for pediatric rare disease diagnosis, backed by one of the world's largest rare disease datasets (GeneDx Infinity™, 2.5M+ tests). Nearly all 2025 revenue was from diagnostic test reports reimbursed by third-party... Read more
Sell if holding. Engine safety override at $53.42: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 32%; Below-average business quality; Negative price momentum. Chart setup: Death cross but MACD improving, RSI 71. Score 5.6/10, moderate confidence.
Passes 5/9 gates (favorable risk/reward ratio, news events none recent, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — GeneDx Holdings Corp.
Latest news
- NEWS Insider sells Class A stock at WGS (NASDAQ: WGS) — multiple lots reported - Stock Titan — Stock Titan negative
- NEWS Earnings Preview: WGS to Report Financial Results Post-market on May 04 - Moomoo — Moomoo neutral
- NEWS Jefferies reiterates GeneDx stock rating citing market penetration - Investing.com — Investing.com positive
- NEWS WGS Stock Slumps After Hours As Firm Predicts Lower Test Volume For Year - Stocktwits — Stocktwits negative
- NEWS Craig-Hallum reaffirms buy on GeneDx (WGS) with $153 price target - MSN — MSN positive
Generated 2026-06-09T22:16:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierlimited number of suppliers10-K Item 1: 'We rely on a limited number of suppliers, including Illumina, Inc., Life Technologies Corporation, Twist Biosciences Corporation, Path-Tec LLC and Agilent Technologies. for certain laboratory reagents'
Material Events(8-K, last 90d)
- 2026-03-02Item 1.02MEDIUMGeneDx terminated its existing credit agreement with Perceptive Credit Holdings IV, LP on February 27, 2026 upon entering a new $100M term loan with Blackstone. Perceptive facility repaid in full.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -17.6%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $53.42: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 32%; Below-average business quality; Negative price momentum. Chart setup: Death cross but MACD improving, RSI 71. Prior stop was $48.17. Score 5.6/10, moderate confidence.
Take-profit target: $66.99 (+29.3% upside). Prior stop was $48.17. Stop-loss: $48.17.
Concentration risk — Supplier: limited number of suppliers; Quality below floor (3.9 < 4.0); Value-trap signals (2/5): Margin compression (op margin 1.0%), Material insider selling (8 sells, 0.20% of cap).
GeneDx Holdings Corp. trades at a P/E of N/A (forward 42.4). TrendMatrix value score: 7.5/10. Verdict: Sell.
13 analysts cover WGS with a consensus score of 4.2/5. Average price target: $77.
What does GeneDx Holdings Corp. do?GeneDx provides exome and whole genome sequencing primarily for pediatric rare disease diagnosis, backed by one of the...
GeneDx provides exome and whole genome sequencing primarily for pediatric rare disease diagnosis, backed by one of the world's largest rare disease datasets (GeneDx Infinity™, 2.5M+ tests). Nearly all 2025 revenue was from diagnostic test reports reimbursed by third-party payors; ~1.5% of revenues are from outside the U.S. The proprietary dataset creates a diagnostic flywheel—each new test improves interpretation accuracy.